Search results for " stroke"

showing 10 items of 328 documents

Global, regional, and national burden of stroke and its risk factors, 1990–2019 : a systematic analysis for the Global Burden of Disease Study 2019

2021

Background Regularly updated data on stroke and its pathological types, including data on their incidence, prevalence, mortality, disability, risk factors, and epidemiological trends, are important for evidence-based stroke care planning and resource allocation. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) aims to provide a standardised and comprehensive measurement of these metrics at global, regional, and national levels. Methods We applied GBD 2019 analytical tools to calculate stroke incidence, prevalence, mortality, disability-adjusted life-years (DALYs), and the population attributable fraction (PAF) of DALYs (with corresponding 95% uncertainty intervals [UIs]…

MaleAging030204 cardiovascular system & hematologyStroke dataGUIDELINES3124 Neurology and psychiatryBody Mass IndexGlobal Burden of Disease0302 clinical medicineRA0421Risk FactorsEpidemiologyStrokesYOUNG-ADULTSPrevalence80 and overAetiology610 Medicine & healthStrokePOPULATION1103 Clinical Sciences 1109 NeurosciencesCause of deathAged 80 and overeducation.field_of_studyMortality rateIncidence (epidemiology)Incidence1. No povertyArticlesHälsovetenskaperMiddle AgedStroke typesddc:3. Good healthStrokeISCHEMIC-STROKEIncomeFemaleQuality-Adjusted Life YearsLife Sciences & BiomedicineAdultmedicine.medical_specialtyGBDPopulationClinical SciencesClinical Neurology610 Medicine & health03 medical and health sciencesClinical ResearchMIDDLE-INCOME COUNTRIESHealth SciencesmedicineHumansRisk factoreducationGBD 2019 Stroke CollaboratorsCerebral HemorrhageAgedIschemic StrokeGlobal burdenScience & TechnologyNeurology & NeurosurgeryHYPERTENSIONbusiness.industryMORTALITYPrevention3112 NeurosciencesNeurosciences1103 Clinical SciencesSERVICESSubarachnoid Hemorrhagemedicine.diseasePREVENTIONBrain DisordersGood Health and Well BeingAttributable riskHuman medicineNeurology (clinical)Neurosciences & Neurologybusiness1109 Neurosciences030217 neurology & neurosurgeryDemography2.4 Surveillance and distributionRC
researchProduct

Analysis of polymorphisms Leiden Factor V G1691A and prothrombin G20210A as risk factors for acute myocardial infarction.

2011

Thrombotic risk increases in elderly, therefore, the understanding of the genetic predisposition of hypercoagulability could make the difference in the prevention of venous and/or arterial thrombotic events. Laboratory evaluation of hyperfibrinogenemia, increased Factor VII levels, antiphospholipid antibodies presence and hyperhomocysteinemia are considered to have a consistent high predictivity for arterial thrombophilic diseases. Anyway, a large debate exists on the validity of testing Leiden Factor V (FV) G1691A and/or prothrombin (FII) G20210A polymorphisms in patients affected by arterial thrombotic diseases, despite of the several observations described. Here we report data strongly s…

MaleAgingmedicine.medical_specialtyHyperhomocysteinemiaLeiden Factor V; Prothrombin; Stroke; Guidelines; Arterial thrombosis.Myocardial InfarctionHyperfibrinogenemiaGuidelineGUIDELINESGastroenterologyCohort Studieschemistry.chemical_compoundInternal medicineArterial DisorderGenotypeGenetic predispositionmedicineHumansGenetic Predisposition to DiseaseMyocardial infarctionAgedAged 80 and overPolymorphism GeneticFactor VIIbusiness.industryFactor VMiddle Agedmedicine.diseaseSurgeryStrokeTHROMBOSISchemistryArterial thrombosis.Prothrombin G20210AFemaleProthrombinGeriatrics and GerontologybusinessGerontologyLeiden Factor V
researchProduct

''Comparative Effect of Treadmill Exercise on Mature BDNF Production in Control versus Stroke Rats''

2012

Quirie, Aurore | Hervieu, Marie | Garnier, Philippe | Demougeot, Celine | Mossiat, Claude | Bertrand, Nathalie | Martin, Alain | Marie, Christine | Prigent-Tessier, Anne; International audience; ''Physical exercise constitutes an innovative strategy to treat deficits associated with stroke through the promotion of BDNF-dependent neuroplasticity. However, there is no consensus on the optimal intensity/duration of exercise. In addition, whether previous stroke changes the effect of exercise on the brain is not known. Therefore, the present study compared the effects of a clinically-relevant form of exercise on cerebral BDNF levels and localization in control versus stroke rats. For this purpo…

MaleBEHAVIORAL RECOVERYTropomyosin receptor kinase BBiochemistryHippocampus0302 clinical medicineNerve Growth FactorHippocampus (mythology)StrokeCerebral Cortex0303 health sciencesNeuronal PlasticityMultidisciplinaryMOTOR RECOVERYQRTRKBNeurochemistryStrokemedicine.anatomical_structureNeurologyOrgan SpecificityCerebral cortex[ SCCO.NEUR ] Cognitive science/NeuroscienceMedicineNeurochemicalsmedicine.symptomResearch ArticleEXPRESSIONmedicine.medical_specialtyHIPPOCAMPAL PLASTICITYCORTEXCerebrovascular DiseasesAnimal TypesScienceBlotting WesternSynaptophysinEnzyme-Linked Immunosorbent AssayPhysical exerciseCONTROLLED-TRIALLesion03 medical and health sciencesPhysical Conditioning AnimalInternal medicineNeuroplasticitymedicineAnimalsLaboratory AnimalsSports and Exercise MedicineProtein PrecursorsRats WistarBiologyIschemic Stroke030304 developmental biologyBrain-derived neurotrophic factorbusiness.industry[SCCO.NEUR]Cognitive science/NeuroscienceBrain-Derived Neurotrophic FactorTRKB''AXONAL-TRANSPORTmedicine.diseaseCorpus StriatumRatsDisease Models AnimalEndocrinology''FOCAL BRAIN ISCHEMIAnervous systemFOCAL BRAIN ISCHEMIAExercise TestPhysical therapyBlood VesselsVeterinary ScienceEndothelium Vascularbusiness030217 neurology & neurosurgerySynaptic PlasticityNeuroscienceNEUROTROPHIC FACTOR
researchProduct

Recanalization Therapies in Acute Ischemic Stroke Patients Impact of Prior Treatment With Novel Oral Anticoagulants on Bleeding Complications and Out…

2015

Background— We explored the safety of intravenous thrombolysis (IVT) or intra-arterial treatment (IAT) in patients with ischemic stroke on non-vitamin K antagonist oral anticoagulants (NOACs, last intake <48 hours) in comparison with patients (1) taking vitamin K antagonists (VKAs) or (2) without previous anticoagulation (no-OAC). Methods and Results— This is a multicenter cohort pilot study. Primary outcome measures were (1) occurrence of intracranial hemorrhage (ICH) in 3 categories: any ICH (ICH any ), symptomatic ICH according to the criteria of the European Cooperative Acute Stroke Study II (ECASS-II) (sICH ECASS-II ) and the National Institute of Neurological Disorders and Stroke …

MaleBrain Ischemia/blood/drug therapyVitamin Kmedicine.medical_treatmentendovascular proceduresAnticoagulants/administration & dosage/adverse effects/classification/therapeutic useAdministration OralPilot ProjectsTissue plasminogen activatorBrain IschemiaCohort Studies2737 Physiology (medical)Atrial Fibrillation80 and overThrombolytic TherapyVitamin K/antagonists & inhibitorsStrokethrombolytic therapyAged 80 and overIncidenceAtrial fibrillationThrombolysisMiddle Aged3. Good healthvitamin K antagonistsTreatment OutcomeAdministrationAcute DiseaseCohortCerebral Hemorrhage/chemically induced/epidemiologyFemaleCardiology and Cardiovascular MedicineAtrial Fibrillation/complicationsmedicine.drugOralmedicine.medical_specialtyanticoagulantsnon-vitamin K antagonist oral anticoagulantsFactor Xa Inhibitors/administration & dosage/adverse effects/therapeutic useintracranial hemorrhagesintra-arterial treatment610 Medicine & healthAntithrombins2705 Cardiology and Cardiovascular MedicineDabigatranFibrinolytic AgentsPhysiology (medical)Internal medicinemedicineischemic strokeHumansAgedCerebral HemorrhageIntracerebral hemorrhageFibrinolytic Agents/therapeutic usebusiness.industryAntithrombins/administration & dosage/adverse effects/therapeutic usemedicine.diseaseddc:616.810040 Clinic for Neurologyanticoagulants; endovascular procedures; intra-arterial treatment; intracranial hemorrhages; ischemic stroke; non-vitamin K antagonist oral anticoagulants; thrombolytic therapy; vitamin K antagonistsPropensity score matchingbusinessFactor Xa InhibitorsCirculation
researchProduct

Vestibular compensation in cerebellar stroke patients.

2014

Background and purpose There is little evidence about the site where compensatory vestibular mechanisms in patients with cerebellar strokes take place. Methods To determine whether the location of a cerebellar lesion might be a crucial variable in vestibular compensation a sample of 22 patients with cerebellar stroke were tested for graviceptive function in the acute and chronic stage. Results Our statistical anatomical lesion analysis indicated that mainly lesions of the cerebellar hemispheres (lobule V, VI, VIIa) hinder vestibular compensation and might lead to an overcompensation. Conclusions Overcompensation-induced dysfunction can be explained by the absence of cerebellar inhibitory si…

MaleCerebellumInhibitory postsynaptic potentialCerebellar Diseasesphysiopathology [Vestibule Labyrinth]otorhinolaryngologic diseasesMedicineCerebellar strokeHumansIn patientddc:610StrokeAgedVestibular systemChronic stagephysiopathology [Stroke]pathology [Cerebellar Diseases]business.industryMiddle AgedVestibular Function Testsmedicine.diseaseCerebellar lesionMagnetic Resonance Imagingphysiopathology [Cerebellar Diseases]Strokemedicine.anatomical_structurenervous systemNeurologypathology [Stroke]FemaleNeurology (clinical)Vestibule LabyrinthbusinessNeuroscienceEuropean journal of neurology
researchProduct

Global, regional, and national burden of stroke, 1990-2016

2019

Background: Stroke is a leading cause of mortality and disability worldwide and the economic costs of treatment and post-stroke care are substantial. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) provides a systematic, comparable method of quantifying health loss by disease, age, sex, year, and location to provide information to health systems and policy makers on more than 300 causes of disease and injury, including stroke. The results presented here are the estimates of burden due to overall stroke and ischaemic and haemorrhagic stroke from GBD 2016. Methods: We report estimates and corresponding uncertainty intervals (UIs), from 1990 to 2016, for incidence, preval…

MaleCost effectivenessIMPACTGlobal HealthGUIDELINES3124 Neurology and psychiatryBrain IschemiaGlobal Burden of DiseaseCOST-EFFECTIVENESS0302 clinical medicineRisk FactorsGlobal healthPrevalenceMedicine030212 general & internal medicineStrokePOPULATIONAged 80 and overRISKeducation.field_of_studyIncidence (epidemiology)Mortality rateIncidenceAge FactorsMiddle AgedPREVALENCEStrokeFemaleLife Sciences & BiomedicineIntracranial HemorrhagesAdultPopulationClinical Neurology03 medical and health sciencesHumanseducationAgedScience & TechnologyNeurology & Neurosurgerybusiness.industry3112 NeurosciencesKlinisk medicin1103 Clinical Sciencesmedicine.diseaseGBD 2016 Stroke CollaboratorsVerbal autopsyTRANSIENT ISCHEMIC ATTACKYears of potential life lostSocioeconomic FactorsHuman medicineNeurosciences & NeurologyNeurology (clinical)Clinical Medicine1109 NeurosciencesbusinessPRIMARY PREVENTION030217 neurology & neurosurgeryDemographyRCLancet Neurology
researchProduct

Search for Stroke-Protecting Agents in Endothelin-1-Induced Ischemic Stroke Model in Rats

2012

Background and Objective. Ischemic stroke may initiate a reperfusion injury leading to brain damage cascades where inflammatory mechanisms play a major role. Therefore, the necessity for the novel stroke-protecting agents whose the mechanism of action is focused on their anti-inflammatory potency is still on the agenda for drug designers. Our previous studies demonstrated that cerebrocrast (a 1,4-dihydropyridine derivative) and mildronate (a representative of the aza-butyrobetaine class) possessed considerable anti-inflammatory and neuroprotective properties in different in vitro and in vivo model systems. The present study investigated their stroke-protecting ability in an endothelin-1 (ET…

MaleDihydropyridinesDrug Evaluation PreclinicalInfarctionBrain damagePharmacologyNeuroprotectionIn vivomedicineAnimalsRats WistarStrokeEndothelin-1business.industryGeneral Medicinemedicine.diseaseRatsStrokeDisease Models AnimalNeuroprotective AgentsMechanism of actionendothelin-1; ischemic stroke; neurodegeneration; protection; cerebrocrast; mildronateDrug Therapy Combinationmedicine.symptombusinessReperfusion injuryEx vivoMethylhydrazinesMedicina; Volume 48; Issue 10; Pages: 77
researchProduct

The association between new onset atrial fibrillation and incident cancer—A nationwide cohort study

2018

A recent analysis showed an association with new onset atrial fibrillation (NOAF) and incident cancer among women. We aimed to examine the risk of cancer among patients with NOAF in general population. A retrospective cohort of 5130 patients with NOAF was identified from a random sample of one million subjects between 2005 and 2010 from Taiwan National Health Insurance Research Database. The standard incidence ratio of incident cancer and hazard ratios were calculated by modeling cumulative incidence with competing risk of death. During a mean follow-up duration of 3.4 years, 330 patients developed cancer. The standard incidence ratio of all malignancies was 1.41 (95% confidence interval 1.…

MaleEconomicslcsh:MedicineSocial Sciences030204 cardiovascular system & hematologyVascular MedicineBrain Ischemia0302 clinical medicineRisk FactorsNeoplasmsEpidemiology of cancerAtrial FibrillationMedicine and Health SciencesGenitourinary CancersCumulative incidence030212 general & internal medicinelcsh:ScienceAged 80 and overeducation.field_of_studyMultidisciplinaryCancer Risk FactorsIncidenceHazard ratioAge FactorsMiddle AgedStrokeOncologyNeurologyFemaleArrhythmiaCohort studyResearch Articlemedicine.medical_specialtyCerebrovascular DiseasesUrologyPopulationCardiology03 medical and health sciencesBreast cancerHealth EconomicsSex FactorsDiagnostic MedicineInternal medicinemedicineCancer Detection and DiagnosisHumanseducationIschemic StrokeAgedColorectal Cancerbusiness.industrylcsh:RCancerCancers and NeoplasmsRetrospective cohort studymedicine.diseaseHealth CareWomen's Healthlcsh:QbusinessHealth InsuranceFollow-Up StudiesPLoS ONE
researchProduct

Liraglutide and cardiovascular outcomes in type 2 diabetes

2016

The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo. The primary composite outcome in the time-to-event analysis was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The primary hypothesis was that liraglutide would be noninferior to placebo with regard to the primary outcome, with a margin of 1.30 for the upper boundary of the 95% confidence interval of the hazard ratio. No adjus…

MaleGastrointestinal DiseasesTreatment outcomeClinical BiochemistryMyocardial InfarctionType 2 diabetes030204 cardiovascular system & hematologylaw.inventionMedicine; Endocrinology0302 clinical medicineRandomized controlled trialAged; Cardiovascular Diseases; Diabetes Mellitus Type 2; Double-Blind Method; Female; Gastrointestinal Diseases; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Myocardial Infarction; Stroke; Treatment Outcome; Medicine (all)lawCardiovascular DiseaseClinical-trial; Pancreatitis; Therapies; Cancer; Drugs11 Medical and Health SciencesResearch Support Non-U.S. Gov'tMedicine (all)PANCREATITISHazard ratioLEADER Steering CommitteeFollow up studiesGeneral MedicineMiddle AgedAlbiglutideMulticenter StudyStrokeTRIALSTreatment OutcomeCardiovascular DiseasesRandomized Controlled TrialFemaleLife Sciences & BiomedicineCardiovascular outcomesmedicine.drugHumanmedicine.medical_specialtyGastrointestinal DiseaseMEDLINE030209 endocrinology & metabolismLEADER Trial InvestigatorsPlaceboFollow-Up Studie03 medical and health sciencesMedicine General & InternalResearch Support N.I.H. ExtramuralDouble-Blind MethodGeneral & Internal MedicineDiabetes mellitusInternal medicinemedicineJournal ArticleHumansHypoglycemic AgentsAgedGlycemic efficacyScience & TechnologyHypoglycemic AgentLiraglutidebusiness.industrySemaglutideLiraglutidemedicine.diseaseSurgeryDiabetes Mellitus Type 2businessFollow-Up Studies
researchProduct

Stroke mortality and trends from 1990 to 2006 in 39 countries from Europe and Central Asia: implications for control of high blood pressure

2011

Aims The aim of the present study was to extend our understanding of international trends in stroke and major sequelae in Europe and countries peripheral to Europe by assessing: (1) current mortality rates, (2) the most recent 15-year prevalence trends, and (3) the relationship between systolic blood pressure in community surveys and national stroke mortality. Methods and results Data were obtained from the World Health Organization (WHO [www.who.int/whosis/database/mort/table.cfm][1]), and represent national vital statistics as reported by 39 countries (European and Central Asian countries) using a standard format and population-based cardiovascular surveys. Total numbers of deaths by stro…

MaleGerontologyPopulationCentral asiaInternational inequalityStroke mortalityGroup BTrials stroke mortality hypertensionAge DistributionResidence CharacteristicsPrevalencemedicineHumansMortalityeducationStrokeAgededucation.field_of_studybusiness.industryMortality rateMiddle Agedmedicine.diseaseEuropeStrokeBlood pressureHypertensionAsia CentralFemaleCardiology and Cardiovascular MedicinebusinessDemography
researchProduct